Zacks Investment Research on MSN
GSK's chronic hepatitis B drug meets goals in two late-stage studies
GSK plc GSK announced positive results from two phase III studies, B-Well 1 and B-Well 2, which evaluated its investigational chronic hepatitis B (CHB) therapy called bepirovirsen. Both studies met ...
The Hepatitis B Co-care Scheme, allowing eligible individuals to receive a hepatitis B risk assessment, screening and ...
(Yicai) Jan. 21 -- Chinese innovative pharmaceutical company Kawin Technology plummeted today after withdrawing its ...
Worldwide, seven drugs have been registered for the treatment of chronic hepatitis B. These include two interferons (conventional interferon and peginterferon alfa-2a) and five oral NAs (lamivudine, ...
With a $416,000 grant from the National Institutes of Health (NIH), SLU scientists will continue work to cure hepatitis B, building on significant findings published in two recent papers. John Tavis, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results